Roche/HHS ddC agreement
Executive Summary
Roche's licensing agreement with HHS covering exclusive development and marketing of dideoxycytidine has been finalized. The firm will receive marketing exclusivity for 10 years starting from the date of the drug's first commerical sale. Roche is currently in Phase I testing with DDC and is supplying the drug to a multi-center clinical program sponsored by the National Institutes of Health.